Literature DB >> 10595863

Treatment of patients with Paget's disease of bone.

C Roux1, M Dougados.   

Abstract

Paget's disease is a progressive bone disease, monostotic or polyostotic, characterised by hypertrophy of affected bones and accelerated disorganised bone remodelling. It results in bone deformities and pain, with a risk for articular and neurological complications, and fractures. The risk of complications, and thus the therapeutic decision, is a function of the age of the patient, and the severity and the activity of the disease. Bisphosphonates are first-line therapy for Paget's disease, and the advent of the new bisphosphonates permits a dramatic improvement in treatment. The optimal treatment regimen should obtain normalisation or quasi-normalisation of markers of bone remodelling. This result has the potential for a long-term control of the disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595863     DOI: 10.2165/00003495-199958050-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  77 in total

1.  One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray.

Authors:  J Y Reginster; A M Jeugmans-Huynen; A Albert; D Denis; P Franchimont
Journal:  J Bone Miner Res       Date:  1988-06       Impact factor: 6.741

2.  Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.

Authors:  S Patel; D Pearson; D J Hosking
Journal:  Arthritis Rheum       Date:  1995-10

3.  Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis.

Authors:  R P Warrell; B Bosco; S Weinerman; B Levine; J Lane; R S Bockman
Journal:  Ann Intern Med       Date:  1990-12-01       Impact factor: 25.391

4.  Evidence for secular change in Paget's disease.

Authors:  T Cundy; K McAnulty; D Wattie; G Gamble; M Rutland; H K Ibbertson
Journal:  Bone       Date:  1997-01       Impact factor: 4.398

5.  A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone.

Authors:  D Thiébaud; P Jaeger; C Gobelet; A F Jacquet; P Burckhardt
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

6.  Absence of paramyxovirus RNA in cultures of pagetic bone cells and in pagetic bone.

Authors:  M A Birch; W Taylor; W D Fraser; S H Ralston; C A Hart; J A Gallagher
Journal:  J Bone Miner Res       Date:  1994-01       Impact factor: 6.741

7.  Osteoarthritis and Paget's disease.

Authors:  P S Helliwell
Journal:  Br J Rheumatol       Date:  1995-11

8.  Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.

Authors:  D L Douglas; T Duckworth; J A Kanis; C Preston; D J Beard; T W Smith; I Underwood; J S Woodhead; R G Russell
Journal:  Arthritis Rheum       Date:  1980-10

9.  Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP).

Authors:  C C Johnston; R D Altman; R E Canfield; G A Finerman; J D Taulbee; M L Ebert
Journal:  Clin Orthop Relat Res       Date:  1983 Jan-Feb       Impact factor: 4.176

10.  Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone.

Authors:  R D Altman
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

View more
  12 in total

1.  Monostotic Paget's disease of the tibia in Korea.

Authors:  Chan-Hee Lee; Sung-Hun Han; Bo-Young Yoon; Yun-Woo Lee
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.

Authors:  Johanna Räikkönen; Julie C Crockett; Michael J Rogers; Hannu Mönkkönen; Seppo Auriola; Jukka Mönkkönen
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

6.  Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation.

Authors:  Myung Hee Moon; Jae Kyo Jeong; Jae Suk Seo; Jae Won Seol; You Jin Lee; Meilang Xue; Christopher J Jackson; Sang-Youel Park
Journal:  Exp Mol Med       Date:  2011-03-31       Impact factor: 8.718

7.  A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.

Authors:  Hannu Mönkkönen; Seppo Auriola; Petri Lehenkari; Maarit Kellinsalmi; Ilmo E Hassinen; Jouko Vepsäläinen; Jukka Mönkkönen
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

8.  Medicinal surface modification of silicon nanowires: impact on calcification and stromal cell proliferation.

Authors:  Ke Jiang; Dongmei Fan; Yamina Belabassi; Giridhar Akkaraju; Jean-Luc Montchamp; Jeffery L Coffer
Journal:  ACS Appl Mater Interfaces       Date:  2009-02       Impact factor: 9.229

9.  Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells.

Authors:  Laura M Mitrofan; Ferran B Castells; Jukka Pelkonen; Jukka Mönkkönen
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

10.  Risedronate inhibits human osteosarcoma cell invasion.

Authors:  Zeng Feng Xin; Yang Kyung Kim; Sung Taek Jung
Journal:  J Exp Clin Cancer Res       Date:  2009-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.